HRP20191655T1 - N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat sol - Google Patents
N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat sol Download PDFInfo
- Publication number
- HRP20191655T1 HRP20191655T1 HRP20191655T HRP20191655T1 HR P20191655 T1 HRP20191655 T1 HR P20191655T1 HR P20191655 T HRP20191655 T HR P20191655T HR P20191655 T1 HRP20191655 T1 HR P20191655T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- treatment
- migraine headaches
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 7
- 208000019695 Migraine disease Diseases 0.000 claims 6
- 206010027603 Migraine headaches Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 238000005259 measurement Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (13)
1. Čvrsta farmaceutska kompozicija u doznom jediničnom obliku, koja sadrži, po dozi, od 1 mg do 1000 mg hemisulfat soli spoja (I):
i farmaceutski prihvatljiv nosač ili razblaživač.
2. Farmaceutska kompozicija u formi oralnog doznog oblika, koji sadrži od 70 mg do 750 mg hemisulfat soli spoja (I) u skladu sa patentnim zahtjevom 1.
3. Farmaceutska kompozicija u skladu sa patentnim zahtjevom 2, koja sadrži 70 mg hemisulfat soli spoja (I).
4. Farmaceutska kompozicija u skladu sa patentnim zahtjevom 2, koja sadrži 80 mg hemisulfat soli spoja (I).
5. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 4 gdje hemisulfat sol spoja (I) je seskvihidrat.
6. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 5 gdje hemisulfat sol spoja (I) je kristalni oblik H1.5-1 koji je naznačen sljedećim:
parametri jedinične stanice suštinski jednaki sljedećim:
Prostorna grupa: P21212
Molekule spoja (I)/asimetrična jedinica: 1
Zapremina = 2851 Å3
Gustoća (izračunato) = 1.423 g/cm3,
pri čemu je mjerenje navedenog kristalnog oblika na temperaturi od oko 25°C.
7. Farmaceutska kompozicija u skladu sa patentnim zahtjevom 6 gdje je navedeni oblik H1.5-1 naznačen sa jednim ili više od sljedećeg:
a) shema rendgenske difrakcije na prahu (CuKα λ=1.5418Å) koji sadrži sljedeće 2θ vrijednosti: 5.4±0.1, 8.6±0.1, 9.7±0.1, 12.4±0.1, 14.9±0.1,17.6±0.1, 18.1±0.1, 20.5±0.1, 21.4±0.1, i 22.0±0.1, pri čemu je mjerenje kristalnog oblika na temperaturi od oko 25°C;
i/ili
b) spektri nuklearne rezonance u čvrstom stanju koji sadrže sljedeće pikove (δ (ppm) navedeni kao TMS): 26.6±0.1, 27.1±0.1, 28.3±0.1, 30.7±0.1, 43.1±0.1, 45.9±0.1, 47.1±0.1, 52.0±0.1, 54.2±0.1, 72.5±0.1, 117.0±0.1, 117.7±0.1, 124.2±0.1, 125.2±0.1, 128.3±0.1, 130.3±0.1, 131.4±0.1, 134.1±0.1, 140.8±0.1, 144.7±0.1, 148.7±0.1, 149.8±0.1, 151.2±0.1, 153.4±0.1, 155.1±0.1, 155.6±0.1, i 156.7±0.1.
8. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za primjenu u liječenju migrenskih glavobolja.
9. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za oralno administriranje koje je korisno za liječenje migrenskih glavobolja.
10. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za sublingvalno administriranje koje je korisno za liječenje migrenskih glavobolja.
11. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za intranazalno administriranje koje je korisno za liječenje migrenskih glavobolja.
12. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za primjenu jednom dnevno u liječenju migrenskih glavobolja.
13. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za primjenu dva puta dnevno u liječenju migrenskih glavobolja.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261603598P | 2012-02-27 | 2012-02-27 | |
EP17180587.2A EP3254681B1 (en) | 2012-02-27 | 2013-02-25 | N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191655T1 true HRP20191655T1 (hr) | 2019-12-13 |
Family
ID=47844498
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171620TT HRP20171620T1 (hr) | 2012-02-27 | 2017-10-25 | N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol |
HRP20191655 HRP20191655T1 (hr) | 2012-02-27 | 2019-09-16 | N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat sol |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171620TT HRP20171620T1 (hr) | 2012-02-27 | 2017-10-25 | N- (5s, 6s, 9r) - 5 amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h - imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna sol |
Country Status (25)
Country | Link |
---|---|
US (1) | US8759372B2 (hr) |
EP (2) | EP3254681B1 (hr) |
JP (2) | JP6208154B2 (hr) |
KR (2) | KR102220969B1 (hr) |
CN (1) | CN104136437B (hr) |
AU (1) | AU2013226361B2 (hr) |
BR (1) | BR112014021032B1 (hr) |
CA (1) | CA2865585C (hr) |
CY (2) | CY1119448T1 (hr) |
DK (2) | DK2820016T3 (hr) |
EA (1) | EA025358B1 (hr) |
ES (2) | ES2642737T3 (hr) |
HK (1) | HK1248111B (hr) |
HR (2) | HRP20171620T1 (hr) |
HU (2) | HUE047050T2 (hr) |
IL (1) | IL234272B (hr) |
LT (2) | LT3254681T (hr) |
MX (1) | MX352171B (hr) |
NO (1) | NO2935439T3 (hr) |
PL (2) | PL2820016T3 (hr) |
PT (2) | PT3254681T (hr) |
RS (2) | RS56556B1 (hr) |
SG (1) | SG11201404834XA (hr) |
SI (2) | SI3254681T1 (hr) |
WO (1) | WO2013130402A1 (hr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX347229B (es) | 2012-01-26 | 2017-04-19 | Christopher J Soares | Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso. |
BR112014021032B1 (pt) * | 2012-02-27 | 2022-09-27 | Bristol-Myers Squibb Company | Sal hemissulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluoro-fenil)-6,7,8,9-tetra-hidro-5h- iclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il}-piperidina-1-carboxilato, seu uso e composição farmacêutica que o compreende |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
KR20220025914A (ko) | 2015-03-06 | 2022-03-03 | 아테아 파마슈티컬즈, 인크. | HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드 |
IL265099B1 (en) * | 2016-09-02 | 2024-05-01 | Christopher J Soares | Medicinal compositions containing an effective amount of a calcitonin gene-related peptide (CGRP) receptor antagonist, or a pharmaceutically acceptable salt thereof, for the treatment of glaucoma |
KR20190043602A (ko) | 2016-09-07 | 2019-04-26 | 아테아 파마슈티컬즈, 인크. | Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드 |
MY201105A (en) | 2017-02-01 | 2024-02-06 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
KR20200135465A (ko) * | 2018-03-25 | 2020-12-02 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | Cgrp 관련 장애를 위한 리메게판트 |
EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
US20210338654A1 (en) * | 2019-01-20 | 2021-11-04 | Biohaven Pharmaceutical Holding Company Ltd. | Cgrp antagonists for treating migraine breakthrough |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
KR20230157986A (ko) | 2021-03-02 | 2023-11-17 | 체게에르페 다이어그노스틱스 게엠베하 | 편투통 발생의 치료 및/또는 저감 |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
AR126954A1 (es) * | 2021-09-02 | 2023-12-06 | Biohaven Pharm Holding Co Ltd | Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp |
CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
CN116554164A (zh) * | 2022-01-27 | 2023-08-08 | 奥锐特药业(天津)有限公司 | 一种瑞美吉泮的制备方法 |
WO2023175632A1 (en) * | 2022-03-17 | 2023-09-21 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA24500A1 (fr) * | 1997-03-21 | 1998-10-01 | Lg Life Sciences Ltd | Derive du sel d'acide carboxylique de naphthyridine . |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
WO2005085228A1 (ja) | 2004-03-05 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd. | シクロアルカノピリジン誘導体 |
CA2583536A1 (en) | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
EP1804919B1 (en) | 2004-10-22 | 2011-03-30 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
CA2649158A1 (en) | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Process for the preparation of pyridine heterocycle cgrp antagonist intermediate |
DE102006017827A1 (de) * | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue kristalline Verbindungen |
US8143403B2 (en) | 2008-04-11 | 2012-03-27 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8314117B2 (en) * | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
US8748429B2 (en) | 2011-04-12 | 2014-06-10 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
BR112014021032B1 (pt) * | 2012-02-27 | 2022-09-27 | Bristol-Myers Squibb Company | Sal hemissulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluoro-fenil)-6,7,8,9-tetra-hidro-5h- iclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il}-piperidina-1-carboxilato, seu uso e composição farmacêutica que o compreende |
-
2013
- 2013-02-25 BR BR112014021032-2A patent/BR112014021032B1/pt active IP Right Grant
- 2013-02-25 EP EP17180587.2A patent/EP3254681B1/en active Active
- 2013-02-25 DK DK13708603.9T patent/DK2820016T3/da active
- 2013-02-25 JP JP2014558927A patent/JP6208154B2/ja active Active
- 2013-02-25 CN CN201380011305.6A patent/CN104136437B/zh active Active
- 2013-02-25 WO PCT/US2013/027648 patent/WO2013130402A1/en active Application Filing
- 2013-02-25 PL PL13708603T patent/PL2820016T3/pl unknown
- 2013-02-25 PL PL17180587T patent/PL3254681T3/pl unknown
- 2013-02-25 KR KR1020207003401A patent/KR102220969B1/ko active IP Right Grant
- 2013-02-25 RS RS20171092A patent/RS56556B1/sr unknown
- 2013-02-25 HU HUE17180587A patent/HUE047050T2/hu unknown
- 2013-02-25 ES ES13708603.9T patent/ES2642737T3/es active Active
- 2013-02-25 DK DK17180587.2T patent/DK3254681T3/da active
- 2013-02-25 US US13/775,528 patent/US8759372B2/en active Active
- 2013-02-25 KR KR1020147023856A patent/KR102076118B1/ko active IP Right Grant
- 2013-02-25 CA CA2865585A patent/CA2865585C/en active Active
- 2013-02-25 RS RSP20191191 patent/RS59295B1/sr unknown
- 2013-02-25 AU AU2013226361A patent/AU2013226361B2/en active Active
- 2013-02-25 PT PT171805872T patent/PT3254681T/pt unknown
- 2013-02-25 LT LTEP17180587.2T patent/LT3254681T/lt unknown
- 2013-02-25 MX MX2014009544A patent/MX352171B/es active IP Right Grant
- 2013-02-25 LT LTEP13708603.9T patent/LT2820016T/lt unknown
- 2013-02-25 EA EA201491585A patent/EA025358B1/ru not_active IP Right Cessation
- 2013-02-25 ES ES17180587T patent/ES2746031T3/es active Active
- 2013-02-25 SI SI201331560T patent/SI3254681T1/sl unknown
- 2013-02-25 EP EP13708603.9A patent/EP2820016B1/en active Active
- 2013-02-25 SI SI201330759T patent/SI2820016T1/sl unknown
- 2013-02-25 SG SG11201404834XA patent/SG11201404834XA/en unknown
- 2013-02-25 PT PT137086039T patent/PT2820016T/pt unknown
- 2013-02-25 HU HUE13708603A patent/HUE034936T2/hu unknown
- 2013-12-10 NO NO13811338A patent/NO2935439T3/no unknown
-
2014
- 2014-08-24 IL IL234272A patent/IL234272B/en active IP Right Grant
-
2017
- 2017-09-06 JP JP2017171358A patent/JP6476253B2/ja active Active
- 2017-10-10 CY CY20171101052T patent/CY1119448T1/el unknown
- 2017-10-25 HR HRP20171620TT patent/HRP20171620T1/hr unknown
-
2018
- 2018-06-12 HK HK18107632.9A patent/HK1248111B/zh unknown
-
2019
- 2019-09-11 CY CY20191100951T patent/CY1122121T1/el unknown
- 2019-09-16 HR HRP20191655 patent/HRP20191655T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191655T1 (hr) | N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilat sol | |
HK1149258A1 (en) | Compounds | |
MD20140084A2 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
MY150519A (en) | Imidazoquinolines with immuno-modulating properties | |
GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
MX354102B (es) | Derivados de bencimidazol-prolina. | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
HRP20150356T1 (hr) | Kristalni oblici soli prasugrela | |
IN2014CN04127A (hr) | ||
EP2650293A8 (en) | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof | |
WO2014152996A8 (en) | Crystalline form of a beta-lactamase inhibitor | |
HRP20171824T1 (hr) | (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A | |
MX2015000107A (es) | Derivados de azaindol que actuan como inhibidores de fosfoinositida 3-cinasas (pi3k). | |
SG195106A1 (en) | Trpv4 antagonists | |
EP2786998A4 (en) | THIENYL [3,] 2-D PYRIMIDIN-4-ON COMPOUNDS, METHOD OF MANUFACTURE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | |
RS53900B1 (en) | CRYSTAL FORMS OF HYDROCHLORIDE SALTS (4A-R, 9A-S) -1- (1H-BENZOIMIDAZOL-5-CARBONYL) -2,3,4,4A, 9,9A-HEXAHIDRO-1H-INDENO [2,1-B] PIRIDIN-6-CARBONITRILA AND THEIR USE AS A HSD INHIBITOR 1 | |
WO2012062905A3 (en) | Chromene derivatives and their analoga as wnt pathway antagonists | |
HRP20210158T1 (hr) | Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku | |
WO2014053968A8 (en) | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | |
EP2549874A4 (en) | SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS | |
TN2016000061A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
HRP20180386T1 (hr) | Farmaceutski aktivni spojevi | |
SI2536396T1 (sl) | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan | |
NZ607658A (en) | Heterocyclyl compounds as Histamine H3 receptor ligands | |
MY165623A (en) | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |